# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Samuel Johnson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN008-SYN-TD
- Date: 1765-06-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Catriona Bell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eleven-week review of depression and tics. **S**

## History of present illness

Mr. Johnson returns five weeks after sertraline was increased to 100 mg. He is writing most mornings again and dines with friends several times a week. He wakes less often in dread. He has mild night sweats and no other side effects. He has had six of eight sessions of behavioral therapy for tics and uses the competing response for the head-shaking tic in company; the clucking sounds are less frequent. There was no check two weeks after the dose increase. **S**

| Element | Detail |
|---|---|
| Sertraline | 100 mg daily for five weeks |
| Mood | PHQ-9 10 |
| Function | Writing most mornings; seeing friends |
| Tic therapy | Six of eight sessions |
| Side effects | Mild night sweats |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild night sweats; no fever or weight loss |
| Neurological | Positive | Tics less frequent |
| Psychiatric | Negative | Mood much better; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Sertraline 100 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 98.6 kg; BMI 29.4 kg/m². All vital signs are synthetic.

PHQ-9: 10. All results are synthetic.

## Change since baseline

- PHQ-9: 21 at baseline, 10 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 76 |
| Neurological | Fewer head-turning tics and sounds during the visit |
| Psychiatric | Brighter; humorous and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent** (F33.2). Response: PHQ-9 10, a 52% fall from 21, not yet remission. Night sweats are a known, mild sertraline effect. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Continue sertraline 100 mg daily.
   - Psychotherapy every two weeks.
2. **Tourette syndrome** (F95.2). Yale Global Tic Severity Scale: total tic score 26, from 30; impairment 10, from 20. **S**
   - Finish the eight sessions and keep practicing.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Depression measure (PHQ-9) | At baseline and at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 10: response, not yet remission |
| Medication safety | Sertraline adherence and adverse effects | Every visit in the acute phase; reassess at 2 weeks after starting and after each dose change | Completed today | Mild night sweats; adherent |
| Medication safety | Reassessment two weeks after the sertraline dose increase | Two weeks after each dose change | Deferred | Protocol deviation: no check two weeks after the increase to 100 mg; the next contact was today, five weeks later. No harm resulted: no activation, no new suicidal thoughts, and PHQ-9 fell to 10. Corrective action: a nurse phone check two weeks after any future dose change |
| Survey | Suicide-risk review (PHQ-9 item 9 and structured questions since the last visit), safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm |
| Referral | Psychotherapy (cognitive behavioral therapy with behavioral activation) | Offer to all with moderate or severe depression | Completed today | Ten sessions; now every two weeks |
| Survey | Anxiety measure (GAD-7) | At baseline and with PHQ-9 reviews | Up to date | 9 five weeks ago |
| Survey | Tic severity (Yale Global Tic Severity Scale, recorded in the note; no LOINC code is used) | At diagnosis and periodically to judge the need for and response to treatment | Completed today | Total tic score 26; impairment 10 |
| Referral | Comprehensive Behavioral Intervention for Tics | Offer as an initial treatment option | Completed today | Six of eight sessions |
| Medication safety | Tic-suppressing medication (alpha-2 agonist, aripiprazole, or other) | When tics cause impairment that behavioral therapy does not relieve | Not indicated | Not needed |

## Goal progress

- PHQ-9 response (at least a 50% fall) by three months and remission (below 5) by six months. In progress; target 1765-09-28. **S**
- Back at daily writing and seeing friends again by three months. Outcome by 1765-06-22: Writing most mornings and dining with friends several times a week. **S**
- Fewer and less disruptive tics, judged by him and by the tic severity scale, by six months. In progress; target 1765-09-28. **S**
- Safety plan in place and reviewed at every visit. In progress; target 1765-09-28. **S**

## Guideline basis

- Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (Pringsheim T, et al. Neurology 2019;92(19):896-906) (2019), American Academy of Neurology
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in five weeks. Six-month review in the autumn. **S**
- Next scheduled visit 1765-07-27: periodic adult preventive visit. **S**
